Searched for
INDIA CRDMO SECTOR
“Reallocate, Diversify, Reposition”: Ajay Srivastava flags rising macro risks for investorsIndian markets face rising macro risks from global shocks, currency pressure, and energy prices, impacting domestic consumption and corpora...- Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge?Syngene shares surged despite a 19% YoY decline in Q4FY26 net profit to Rs 148 crore, as earnings rebounded sharply from Rs 15 crore in the...
- Stick to defensive and quality themes amid volatile global setup: Mayuresh JoshiIndian stock markets are showing a strong rebound. Investors are now carefully selecting companies with good earnings and strong finances. ...
- ETMarkets Smart Talk| Aditya Sood sees multi-year upside in financials and domestic manufacturing themesAditya Sood of InCred Asset Management is bullish on India's market, expecting financials and domestic manufacturing to lead wealth creatio...
- India’s generic pharma faces tariff uncertainty but retains edge in US market: JPMorgan analystIndia’s generic pharma faces tariff uncertainty but retains edge in US market: JPMorgan analyst
- Jefferies' pharma bets are Divi's Laboratories and 3 smallcaps, with up to 30% upside. Here's whyJefferies expects India’s CRDMO sector to see strong growth over 3–5 years, recommending Divi’s Labs, Cohance Lifesciences, Sai Life Scienc...
- Cohance Lifesciences and other pharma stocks jump up to 5% after Jefferies initiates Buy recommendationCohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing stro...
- Avendus Fund, SBI Life lead funding in AragenAvendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...
- Trump tariff assault hits over 40 Indian stocks. Full list across key sectors for stock market investorsIndian markets initially stumbled but recovered following Trump's tariff announcement, with export-heavy sectors like textiles, pharma, and...
- Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...
- TPG offloads Rs 1,505 cr stake in Sai Life via block deals; Norges Bank, MFs step inGlobal investor TPG sold its ₹1,505 crore stake in Sai Life Sciences via block deals at ₹722 per share. Key buyers included Norges Bank and...
- India's contract drug makers seek government support in China fightIndia's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With ...
- India's CRDMO sector can touch USD 25 bn in size by 2035: ReportIndia's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...
- India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...
- Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and SyngeneMacquarie said that the sector is currently at a turning point, driven by increased pharmaceutical outsourcing due to drug pricing pressure...
- Macquarie initiates coverage on Divi’s Labs, 3 CRDMO firms with up to 40% upside potentialThe global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x for regional an...
- Buy Piramal Pharma, target price Rs 340: JM FinancialJM Financial recommends buying Piramal Pharma stock. The target price is Rs 340. The current market price is Rs 260.55. India's CRDMO indus...
- Quadria Capital to pick up minority stake in drug company AragenQuadria Capital is set to acquire a 10% stake in Aragen Life Sciences for about $100 million, valuing the Indian CRDMO at $1.2 billion. The...
- Want to make India a reliable pharmacy of world, says Secretary Department of PharmaceuticalsThe Indian pharmaceutical industry is emerging as a crucial part of the economy, driven by the success of the Make in India initiative and ...
- D-Street Diary: Sai Life, Sanstar, Godrej Consumer & other companies in focusSai Life Sciences, backed by TPG, has filed for a massive ₹5000 crore IPO. Sanstar's IPO opens on July 19. Northern Arc Capital and bulk co...
Load More
